Physician profile
Amanda Kay Williams
NPI 1104147669
$3,476.71
in general payments reported to CMS, 2019-2025
29 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Geriatric Medicine (Family Medicine) provider received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $921 · 2021: $1,072 · 2022: $820 · 2023: $27.67 · 2024: $83.72 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $974.92 | 2020-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $543.27 | 2019-2022 | |
| Novo Nordisk INC | $428.29 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $216.09 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $192.93 | 2020-2022 | |
| Lilly USA, LLC | $164.04 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.40 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $104.65 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.56 | 2019-2022 | |
| Pfizer INC. | $87.77 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $58.54 | 2020-2022 | |
| Upsher-Smith Laboratories LLC | $56.12 | 2020-2021 | |
| Amarin Pharma, INC. | $46.25 | 2019 | |
| Astellas Pharma US INC | $38.78 | 2020-2021 | |
| Corcept Therapeutics | $36.08 | 2025 | Korlym |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $34.89 | 2020-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Teva Pharmaceuticals USA, INC. | $32.40 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $28.43 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $28.00 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.11 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $23.89 | 2021 | |
| Phathom Pharmaceuticals, INC. | $19.09 | 2025 | Voquezna |
| Avvisto Therapeutics, LLC | $18.40 | 2024 | Cycloset |
| Allergan, INC. | $16.97 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.69 | 2019 | |
| Exact Sciences Corporation | $13.31 | 2024 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $12.88 | 2020 | |
| Eisai INC. | $12.60 | 2021 | |
| Glaxosmithkline, LLC. | $11.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.